▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1539 by analyst upside · 2026-06-27
IDYA
IDEAYA Biosciences, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+43.7%
implied upside to consensus target
Current Price $36.74
Consensus Target $52.79
Bull Target $66.0
Bear Target $36.0
Analysts Covering 14
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
10
Hold
2
Sell
0
52-Week Low $20.5
52-Week High $39.28
YTD Return +8.5%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E -10.0x
EPS (TTM) $-1.57
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $225M
Profit Margin -62.2%
52-WEEK RANGE
52-Week Low $20.5
52-Week High $39.28
Current Price $36.74
Bear Target $36.0
Bull Target $66.0
● Now $36.74 ● Target $52.79
TRADING DATA
Avg Volume 1.3M
YTD Return +8.5%
Analyst Count 14
Consensus Buy
Upside to Target +43.7%
Last Updated 2026-06-27

ANALYST SUMMARY

IDEAYA Biosciences, Inc. (IDYA) is currently trading at $36.74 with a Wall Street consensus price target of $52.79, implying potential upside of 43.7% over the next 12 months. 14 analysts currently cover IDYA, with a consensus rating of Buy — 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $66.0, while the most cautious has a target of $36.0.

IDYA operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 8.5% year-to-date and is currently trading near the upper end of its 52-week range of $20.5 – $39.28.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

OPCH +31.0%
Option Care Health, Inc.
$3B · P/E 16.8x · Buy
DOCS +21.7%
Doximity, Inc.
$4B · P/E 20.3x · Buy
ACAD +25.0%
ACADIA Pharmaceuticals Inc.
$4B · P/E 11.5x · Buy
GRFS +47.0%
Grifols, S.A.
$5B · P/E 10.6x · Buy
MMSI +24.8%
Merit Medical Systems, Inc.
$4B · P/E 30.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for IDYA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Wedbush reit
Outperform → Outperform 2026-06-12 Building track record
Wedbush reit
Outperform → Outperform 2026-06-02 Building track record
Mizuho — Reiterated
Outperform → Outperform 2026-05-07 Building track record
Goldman Sachs — Reiterated
Neutral → Neutral 2026-04-14 Building track record
Wells Fargo — Reiterated
Overweight → Overweight 2026-04-14 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-04-14 Building track record
Wedbush — Reiterated
Outperform → Outperform 2026-04-14 Building track record
Guggenheim — Reiterated
Buy → Buy 2026-04-14 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →